- ICH GCP
- US Clinical Trials Registry
- Clinical Trial NCT03799536
Bioequivalence Study of Sotalol, Tablets, 160 mg (Pharmtechnology LLC, Belarus), and Sotalex ®, Tablets, 160 mg (Bristol-Myers Squibb GmbH & Co. KGaA, Germany), in Healthy Volunteers Under Fasting Conditions
June 5, 2019 updated by: Pharmtechnology LLC
Open-label, Randomized, Crossover, Two-period, Two-sequence Bioequivalence Study of Sotalol, Tablets, 160 mg (Pharmtechnology LLC, Belarus), and Sotalex®, Tablets, 160 mg (BRISTOL-MYERS SQUIBB GmbH & Co. KGaA, Germany), in Healthy Volunteers Under Fasting Condition
This is an open-label, randomized, single-center, single-dose, two-treatment, two-sequence, two-period, crossover, comparative study, where each subject was randomly assigned to the reference or the test formulation in each period of the study (sequences RT or TR), in order to evaluate if both formulations are bioequivalent.The study was conducted in multiple groups.
Study Overview
Detailed Description
The objective of this study is to establish if two formulations of sotalol are bioequivalent.
The test formulation is Sotalol Tablets, 160 mg (Pharmtechnology LLC, Belarus).
The reference formulation is Sotalex®, Tablets, 160 mg (Bristol-Myers Squibb GmbH & Co. KGaA, Germany).
36 healthy adult volunteers of both genders with age ranging from 18 to 55 years old will receive a single tablet (160 mg of sotalol) of the test and the reference products with 200 ml of water after an overnight fast of at least 10 hours, according to the pre-defined randomization list.
In the first period, 18 subjects will receive the test product and 18 subjects the reference product.In the second period subjects will receive the products in the opposite order.
Subjects will fast 4 hours after administration of the study drugs during each study period.
Standardized meals will be provided in each study period.
Water will not be accessible to the subjects 1 hour prior to administration of the study drugs and 2 hours after administration of the study drugs in each period.
In each period blood samples were collected before dosing and 0,5 ; 1; 1,5; 2 ; 2,5; 3; 3,5; 4; 4,5; 5; 6; 8; 10; 12; 16; 24; 36; 48; 72 hours after dosing (total number: 19).
The washout period will be 14 days.
A validated HPLC/MS/MS method will be used to determine plasma concentrations of analyte (sotalol).
ANOVA will be performed on log transformed pharmacokinetic parameters Cmax, AUC0-t and 90% confidence interval will be constructed for the ratio of geometric least square means of the test and the reference products, obtained from the log-transformed data.
Bioequivalence will be concluded if the ratio estimate as well as its 90% confidence interval for the analyte, both falls within the acceptable range of 80.00% to 125.00% for Cmax and AUC0-t.
Study Type
Interventional
Enrollment (Actual)
36
Phase
- Phase 1
Contacts and Locations
This section provides the contact details for those conducting the study, and information on where this study is being conducted.
Study Locations
-
-
Minsk Region
-
Settl.Lesnoy, Minsk Region, Belarus, 223040
- National Anti-Doping Laboratory
-
-
Participation Criteria
Researchers look for people who fit a certain description, called eligibility criteria. Some examples of these criteria are a person's general health condition or prior treatments.
Eligibility Criteria
Ages Eligible for Study
16 years to 53 years (Adult)
Accepts Healthy Volunteers
No
Genders Eligible for Study
All
Description
Inclusion Criteria:
- Caucasian men or women aged between 18 to 55 years
- Body mass index 18.5-30 kg/m²
- Subjects who have no signs of disease during the screening, and whose screening is conducted within 21 days after the registration in the trial
- Subjects whose laboratory blood and urine values are within the normal range orof deviations are considered by researchers to be clinically insignificant
- Non-smokers or ex-smokers (defined as completely quitting smoking for at least three months prior to being included in the test)
- No known history of alcohol abuse
- No known history of abuse of drugs (benzodiazepines, opioids, cocaine, barbiturates, amphetamine, etc.)
- Willingness to comply with the protocol requirements regarding the restriction of the consumption of products containing xanthine (coffee, tea, chocolate, cola, etc.) for at least 48 hours and products containing tobacco, alcohol-containing products and beverages, grapefruit and/or its juice, food containing poppy at least 72 hours prior taking the investigational medicinal products and over the course of the study, as well as requirements regarding the intake of food, fluids and physical activity imposed by the study
- Healthy subject according to medical history, physical examination and assessment of basic vital signs
- No significant abnormalities on 12-lead ECG
- No significant abnormalities on the chest x-ray obtained within 12 months prior the start of the study
- Consent of women of childbearing age and male participants to use medically confirmed barrier methods of contraception (from the date of screening to the completion of the study), or surgical sterilization in history, or women in postmenopause (at least 24 months) or hysterectomy in history . If women use hormonal contraceptives,they should stop them at least 60 days prior the planned beginning of the study
- The subject's voluntary willingness to provide written informed consent
- The ability, at disceretion of the researcher, to follow all the requirements of the protocol
- The ability, at judgment of the researcher, to follow all the requirements of the protocol
Exclusion Criteria:
- Known history of allergy
- Known contraindications to the use of investigational products or hypersensitivity to the active substance or components of drugs
- Use of drugs with enzymatic-modifying activity, within 28 days prior the beginning of the study
- Use any over-the-counter or prescription drugs (including vitamins, minerals, herbal remedies, and dietary supplements) within 14 days prior the administration of investigational products and over the course of the study
- Intense physical exercises within 24 hours prior to the administration of investigational products
- Any medical or surgical interventions that can disrupt the function of the hematopoietic system, the gastrointestinal tract (with the exception of appendectomy), the liver, urinary system and other body systems
- Any chronic diseases or conditions of the urinary, cardiovascular, neuroendocrine, immune, central nervous systems, hematopoietic system, gastrointestinal tract, liver, organs of vision and other systems of the body and diabetes in medical history, mental illness in an active phase or the history
- The presence of any hereditary disease
- Participation in any clinical trials within 90 days prior the beginning of the current clincial study
- Oncological diseaes in medical history
- Any blood donation within 90 days prior the beginning of the current clincial study
- Acute infectious diseases within 28 days prior the beginning of the current clincial study as well as positive testing for HIV, hepatitis B and C, and syphilis
- Positive test for alcohol
- Positive urinary screen test for drugs of abuse
- Swallowing problems in mediical history
- Positive urinary pregnancy test
- Breast-feeding
- Known history of venous access difficulties
- Vegetarian diet
- Sitting systolic blood pressure < 110 mm Hg or > 140 mm Hg and/or sitting diastolic blood pressure < 70 mm Hg or > 90 mm Hg.Heart rate <50 or >100 beats per minute at screening check-in
- Values of the standard laboratory and instrumental tests outside of normal limits and are judged as clinically significant by investigators or require additional examination and interpretation.
Study Plan
This section provides details of the study plan, including how the study is designed and what the study is measuring.
How is the study designed?
Design Details
- Primary Purpose: Other
- Allocation: Randomized
- Interventional Model: Crossover Assignment
- Masking: Single
Arms and Interventions
Participant Group / Arm |
Intervention / Treatment |
---|---|
Experimental: Sequence AB
Subjects assigned to sequence AB will receive a single 160 mg dose of the test product Sotalol (1 x 160 mg tablet) marked as A in the sequence in the period 1 and a single 160 mg dose of the reference product Sotalex (1 x 160 mg tablet) marked as B in the sequence in the period 2 .
These treatments will be administered orally with approximately 200 mL of water at ambient temperature, in the morning, following a 10-hour overnight fast.
The tablet must be swallowed whole and must not be chewed or broken.
|
Sotalol, Tablets,160 mg, manufactured by Pharmtechnology LLC, Belarus
Other Names:
|
Active Comparator: Sequence BA
Subjects assigned to sequence BA will receive a single 160 mg dose of the reference product Sotalex (1 x 160 mg tablet) marked as B in the sequence in the period 1 and a single 160 mg dose of the test product Sotalol (1 x 160 mg tablet) marked as A in the sequence in the period 2 .
These treatments will be administered orally with approximately 200 mL of water at ambient temperature, in the morning, following a 10-hour overnight fast.
The tablet must be swallowed whole and must not be chewed or broken.
|
Sotalex, Tablets,160 mg, manufactured by Bristol-Myers Squibb GmbH & Co. KGaA, Germany
Other Names:
|
What is the study measuring?
Primary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Cmax of sotalol for the test and the reference products
Time Frame: Time points: 0,00 (within 30 minutes before dosing) and 0,5; 1; 1,5; 2; 2,5; 3; 3,5; 4; 4,5; 5; 6; 8; 10; 12; 16; 24; 36; 48; 72 hours after dosing
|
Maximum concentration in plasma among observed concentrations at pre-specified time points
|
Time points: 0,00 (within 30 minutes before dosing) and 0,5; 1; 1,5; 2; 2,5; 3; 3,5; 4; 4,5; 5; 6; 8; 10; 12; 16; 24; 36; 48; 72 hours after dosing
|
AUC0-t of sotalol for the test and the reference products
Time Frame: Time points: 0,00 (within 30 minutes before dosing) and 0,5; 1; 1,5; 2; 2,5; 3; 3,5; 4; 4,5; 5; 6; 8; 10; 12; 16; 24; 36; 48; 72 hours after dosing
|
Area under the plasma concentration versus time curve from time 0 to the last measured concentration
|
Time points: 0,00 (within 30 minutes before dosing) and 0,5; 1; 1,5; 2; 2,5; 3; 3,5; 4; 4,5; 5; 6; 8; 10; 12; 16; 24; 36; 48; 72 hours after dosing
|
Secondary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
AUC0-∞ of sotalol for the test and the reference products
Time Frame: Time points: 0,00 (within 30 minutes before dosing) and 0,5; 1; 1,5; 2; 2,5; 3; 3,5; 4; 4,5; 5; 6; 8; 10; 12; 16; 24; 36; 48; 72 hours after dosing
|
Area under the plasma concentration versus time curve from time 0 to to infinite time
|
Time points: 0,00 (within 30 minutes before dosing) and 0,5; 1; 1,5; 2; 2,5; 3; 3,5; 4; 4,5; 5; 6; 8; 10; 12; 16; 24; 36; 48; 72 hours after dosing
|
Tmax of sotalol for the test and the reference products
Time Frame: Time points: 0,00 (within 30 minutes before dosing) and 0,5; 1; 1,5; 2; 2,5; 3; 3,5; 4; 4,5; 5; 6; 8; 10; 12; 16; 24; 36; 48; 72 hours after dosing
|
Time to maximum measured plasma concentration
|
Time points: 0,00 (within 30 minutes before dosing) and 0,5; 1; 1,5; 2; 2,5; 3; 3,5; 4; 4,5; 5; 6; 8; 10; 12; 16; 24; 36; 48; 72 hours after dosing
|
T1/2 of sotalol for the test and the reference products
Time Frame: Time points: 0,00 (within 30 minutes before dosing) and 0,5; 1; 1,5; 2; 2,5; 3; 3,5; 4; 4,5; 5; 6; 8; 10; 12; 16; 24; 36; 48; 72 hours after dosing
|
Elimination or terminal half-life
|
Time points: 0,00 (within 30 minutes before dosing) and 0,5; 1; 1,5; 2; 2,5; 3; 3,5; 4; 4,5; 5; 6; 8; 10; 12; 16; 24; 36; 48; 72 hours after dosing
|
Kel of sotalol for the test and the reference products
Time Frame: Time points: 0,00 (within 30 minutes before dosing) and 0,5; 1; 1,5; 2; 2,5; 3; 3,5; 4; 4,5; 5; 6; 8; 10; 12; 16; 24; 36; 48; 72 hours after dosing
|
Elimination rate constant
|
Time points: 0,00 (within 30 minutes before dosing) and 0,5; 1; 1,5; 2; 2,5; 3; 3,5; 4; 4,5; 5; 6; 8; 10; 12; 16; 24; 36; 48; 72 hours after dosing
|
AUCresid of sotalol for the test and the reference products
Time Frame: Time points: 0,00 (within 30 minutes before dosing) and 0,5; 1; 1,5; 2; 2,5; 3; 3,5; 4; 4,5; 5; 6; 8; 10; 12; 16; 24; 36; 48; 72 hours after dosing
|
Residual area
|
Time points: 0,00 (within 30 minutes before dosing) and 0,5; 1; 1,5; 2; 2,5; 3; 3,5; 4; 4,5; 5; 6; 8; 10; 12; 16; 24; 36; 48; 72 hours after dosing
|
Number of treatment-related adverse events (AE) for the test and the reference products as assessed by guidance predefined in the protocol
Time Frame: 28 days
|
An AE is defined as any untoward medical occurrence in a subject administered an investigational product and which does not necessarily have a causal relationship with the treatment.
The data from participants who had taken at least one investigational product was analyzed.
|
28 days
|
Collaborators and Investigators
This is where you will find people and organizations involved with this study.
Sponsor
Collaborators
Investigators
- Principal Investigator: Anastasia Teteryukova, MD, National Anti-Doping Labaratory
Study record dates
These dates track the progress of study record and summary results submissions to ClinicalTrials.gov. Study records and reported results are reviewed by the National Library of Medicine (NLM) to make sure they meet specific quality control standards before being posted on the public website.
Study Major Dates
Study Start (Actual)
January 9, 2019
Primary Completion (Actual)
February 4, 2019
Study Completion (Actual)
February 11, 2019
Study Registration Dates
First Submitted
January 8, 2019
First Submitted That Met QC Criteria
January 8, 2019
First Posted (Actual)
January 10, 2019
Study Record Updates
Last Update Posted (Actual)
June 7, 2019
Last Update Submitted That Met QC Criteria
June 5, 2019
Last Verified
January 1, 2019
More Information
Terms related to this study
Keywords
Additional Relevant MeSH Terms
Other Study ID Numbers
- BE-SOTL-160- 2018
Plan for Individual participant data (IPD)
Plan to Share Individual Participant Data (IPD)?
Undecided
IPD Plan Description
The Company may provide the individual participant data after privacy protection on the case by case basis
Drug and device information, study documents
Studies a U.S. FDA-regulated drug product
No
Studies a U.S. FDA-regulated device product
No
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.
Clinical Trials on Bioequivalence
-
Pharmtechnology LLCRecruitingBioequivalenceRussian Federation
-
Emzor Pharmaceutical Industries LimitedNot yet recruiting
-
Pharmtechnology LLCClinPharmInvest, LLCNot yet recruitingBioequivalenceRussian Federation
-
Indiana UniversityFood and Drug Administration (FDA)Completed
-
AstraZenecaCompletedBioequivalenceUnited States
-
Future University in EgyptCompleted
-
Cross Research S.A.Zambon SpACompleted
-
Laboratorios Andromaco S.A.Completed
-
Emzor Pharmaceutical Industries LimitedUnknown
-
Jiangsu HengRui Medicine Co., Ltd.Unknown
Clinical Trials on Sotalol
-
Kansas City Heart Rhythm Research FoundationTexas Cardiac Arrhythmia Research Foundation; Munson Medical CenterRecruitingAtrial Fibrillation | Arrhythmias, CardiacUnited States
-
University of Sao Paulo General HospitalRecruitingVentricular Arrythmia | Supraventricular Arrhythmia | Proarrhythmia | Antiarrhythmic Drug Adverse ReactionBrazil
-
University of UtahAltaThera Pharmaceuticals, LLCCompleted
-
SanofiCompletedAtrial FibrillationFrance
-
Assistance Publique - Hôpitaux de ParisCompletedHealthy VolunteersFrance
-
Edgar JaeggiCanadian Institutes of Health Research (CIHR)Active, not recruitingFetal Atrial Flutter Without Hydrops | Fetal Supraventricular Tachycardia Without Hydrops | Fetal Supraventricular Tachycardia With HydropsUnited States, Canada, Germany, Australia, Netherlands, United Kingdom
-
Bristol-Myers SquibbTerminatedAtrial FibrillationCanada, United States
-
Massachusetts General HospitalUniversity of Colorado, Denver; Mayo Clinic; National Heart, Lung, and Blood... and other collaboratorsRecruitingLong QT Syndrome | Drug ToxicityUnited States
-
Shengjing HospitalUnknown
-
Ospedale San DonatoUnknownVentricular Tachycardia | Ventricular Premature ComplexesItaly